Clinical Trials in South Korea / NCT06081803
Active, not recruiting
Phase 3
Evolocumab in STEMI
NCT06081803 · tracked via the Priya Life Science South Korea tracker
Condition(s) studied
ST Elevation Myocardial Infarction
Investigational drug(s) / intervention(s)
Repatha®: Repatha® 140mg x 3 pens subcutaneous injection
Study summary
The goal of this clinical trial is to compare the size of myocardial infarct between evolocumab and control groups in patients with ST segment elevation myocardial infarction who undergoing primary percutaneous coronary intervention(PCI). All study participants will undergo a cardiac MRI 4 weeks after primary reperfusion. The evolocumab group will receive 420 mg before PCI via subcutaneous injection.
Eligibility
Inclusion Criteria:
* Typical ischemic chest pain persists for more than 30 minutes
* An elevation of an ST segment greater than 1 mm in two consecutive leads or new-onset left bundle branch block
* Presenting more than 12 hours after the onset of symptoms
Exclusion Criteria:
* Previous history of myocardial infarction
* Previous history of coronary bypass surgery
* Cardiogenic shock that lasts more than 10 minutes or cardiac arrest
* Occlusion of the left main coronary artery
* Pregnant or have a plan of pregnancy
* Serum creatinine level is \>2.5mg/dL or dialysis is required
Primary outcome measure(s)
- Myocardial infarct size — 1 month after primary reperfusion
assessed by cardiac MRI
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Sejong General Hospital | Bucheon-si | South Korea |
More Sejong General Hospital trials in South Korea
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06081803 on ClinicalTrials.gov ↗ ← All trials in South Korea